Loading...
Loading...
India's paclitaxel imports from HONG KONG total $306 across 1 shipments from 1 foreign suppliers. SHENZHEN KEMAI HEALTHCARE CO LIMITED leads with $306 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include INTAS PHARMACEUTICALS LIMITED. This corridor reflects India's pharmaceutical import demand for paclitaxel โ a concentrated sourcing relationship with select suppliers from HONG KONG.

SHENZHEN KEMAI HEALTHCARE CO LIMITED is the leading Paclitaxel supplier from HONG KONG to India, with import value of $306 across 1 shipments. The top 5 suppliers โ SHENZHEN KEMAI HEALTHCARE CO LIMITED โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SHENZHEN KEMAI HEALTHCARE CO LIMITED | $306 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED | $306 | 1 | 100.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Paclitaxel suppliers from HONG KONG to India include SHENZHEN KEMAI HEALTHCARE CO LIMITED. The leading supplier is SHENZHEN KEMAI HEALTHCARE CO LIMITED with import value of $306 USD across 1 shipments. India imported Paclitaxel worth $306 USD from HONG KONG in total across 1 shipments.
India imported Paclitaxel worth $306 USD from HONG KONG across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Paclitaxel sourced from HONG KONG include INTAS PHARMACEUTICALS LIMITED. The largest buyer is INTAS PHARMACEUTICALS LIMITED with $306 in imports across 1 shipments.
The total value of Paclitaxel imports from HONG KONG to India is $306 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists